CLINICAL TRIALS PROFILE FOR NESINA
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Nesina
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00856284 ↗ | Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus | Completed | Takeda | Phase 3 | 2009-03-01 | The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients. |
| NCT01664624 ↗ | Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes | Completed | AstraZeneca | Phase 1 | 2012-07-01 | The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes. |
| NCT01664624 ↗ | Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes | Completed | Takeda | Phase 1 | 2012-07-01 | The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes. |
| NCT01945216 ↗ | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI" | Completed | Takeda | 2010-07-08 | The purpose of this study is to determine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with type 2 diabetes mellitus who responded inadequately to diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy, and α-glucosidase inhibitor. In addition, examining the safety and efficacy of alogliptin in patients with renal impairment, information on the appropriate dosage of alogliptin according to the severity of impaired renal function should be collected. | |
| NCT01945242 ↗ | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones" | Completed | Takeda | 2011-03-01 | The purpose of this study is to determine the safety and efficacy of long-term combination therapy with alogliptin (Nesina) and thiazolidinediones in patients with type 2 diabetes mellitus who failed to respond adequately to treatment with thiazolidinediones in addition to diet therapy and exercise therapy. | |
| NCT01964950 ↗ | Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea | Completed | Takeda | N/A | 2011-07-01 | The purpose of this study is to examine the safety and efficacy of long-term combination therapy with alogliptin (Nesina) and sulfonylurea in patients with type 2 diabetes mellitus who responded inadequately to treatment with sulfonylurea in addition to diet therapy and exercise therapy. |
| NCT01964963 ↗ | Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus | Completed | Takeda | 2011-08-03 | The purpose of this study is to examine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with mild type 2 diabetes mellitus in the routine clinical setting. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Nesina
Condition Name
Clinical Trial Locations for Nesina
Trials by Country
Clinical Trial Progress for Nesina
Clinical Trial Phase
Clinical Trial Sponsors for Nesina
Sponsor Name
